Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
6.43
+0.32 (5.24%)
Oct 8, 2025, 12:02 PM EDT - Market open
Immuneering Employees
Immuneering had 66 employees as of December 31, 2024. The number of employees decreased by 2 or -2.94% compared to the previous year.
Employees
66
Change (1Y)
-2
Growth (1Y)
-2.94%
Revenue / Employee
n/a
Profits / Employee
-$941,346
Market Cap
406.62M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 66 | -2 | -2.94% |
| Dec 31, 2023 | 68 | -5 | -6.85% |
| Dec 31, 2022 | 73 | 9 | 14.06% |
| Dec 31, 2021 | 64 | 38 | 146.15% |
| Dec 31, 2020 | 26 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMRX News
- 8 days ago - Immuneering Corporation - Special Call - Seeking Alpha
- 11 days ago - Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 - GlobeNewsWire
- 12 days ago - Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst - Seeking Alpha
- 13 days ago - Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi - GlobeNewsWire
- 13 days ago - Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi - GlobeNewsWire
- 13 days ago - Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - GlobeNewsWire
- 22 days ago - Immuneering Appoints Dr. Thomas Schall as Chairman of the Board - GlobeNewsWire
- 4 weeks ago - Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25 - GlobeNewsWire